M

Meridian Bioscience

Develops and distributes diagnostic test kits

Scientist – Upstream Process Development

Full-TimeDeadline 9/3/27
No salary listed
Mid, Senior, Expert
Bachelor's, Master's, PhD
Memphis, TN, USA
In PersonMinimal travel may be required between business units or for scientific and commercial meetings.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A Bachelor's, Master's, or Ph.D. from an accredited institution in a relevant scientific discipline such as Virology, Biochemistry, or Molecular Biology is required.
  • Required relevant research or industrial experience is 10+ years with a Bachelor's degree, 8+ years with a Master's degree, or 0–2+ years with a Ph.D.
  • A demonstrated scientific track record in mammalian cell culture, virus propagation, recombinant protein expression, or upstream bioprocess development is required.
  • Extensive hands-on experience with mammalian cell culture to produce viruses, viral antigens, recombinant proteins, or antibodies is required.
  • Demonstrated experience developing and optimizing adherent and/or suspension cell-culture processes, including culture expansion, media optimization, infection or transfection, and harvest.
  • Ability to design statistically sound experiments, analyze multivariable data, identify process drivers, and convert results into practical process controls and recommendations.
  • Understanding of cell-bank and virus-bank lifecycle management, aseptic technique, contamination control, and biosafety practices.
  • Ability to learn and perform downstream bioprocessing unit operations for the purification of cell culture-derived proteins.
  • Ability to collaborate across development, manufacturing, and quality functions and to train or provide technical direction to laboratory and production personnel.
  • Strong organization and project-management skills, with the ability to prioritize multiple assignments and respond calmly to changing business needs.
  • Proficient technical writing and clear, accurate oral communication of scientific data, conclusions, risks, and recommendations.
  • The work requires repetitive movements, including pipetting and computer work, concentration, data analysis, and solving complex technical problems throughout the workday.
  • The role may require occasional work outside normal business hours, including evenings or weekends, to support time-sensitive cultures, production activities, or other business needs.
Responsibilities
  • Design, execute, and optimize upstream processes for virus propagation and recombinant protein expression, primarily using mammalian cell culture, from laboratory-scale vessels through rocking and stirred-tank bioreactors.
  • Develop scalable seed-train and production workflows, including cell-line and host-cell selection, culture expansion, inoculation strategy, media and feed optimization, process monitoring, harvest timing, and primary recovery.
  • Develop and optimize viral production processes by evaluating host-cell performance, multiplicity of infection, infection conditions, harvest criteria, clarification, formulation, storage, and stability.
  • Develop and characterize mammalian expression processes for recombinant proteins and antibodies using adherent or suspension culture, and support other expression platforms when required by the project.
  • Apply risk-based experimental design and statistical tools to identify and characterize critical process parameters and their effects on yield, productivity, product quality, and process reproducibility.
  • Develop and characterize workflows for maintaining cell lines, cell banks, virus seed stocks, and virus banks, including propagation, storage, stability, documentation, and traceability.
  • Establish and use fit-for-purpose in-process and characterization methods for cell growth, viability, metabolites, protein expression, viral concentration, infectious titer, identity, integrity, and stability.
  • Partner with downstream and analytical scientists to define harvest and clarification conditions that protect product quality and enable efficient purification of cell-culture-derived materials.
  • Troubleshoot manufacturing and product-performance issues using structured root-cause analysis, and recommend and implement scientifically justified process improvements and corrective actions.
  • Learn and apply protein purification techniques for the purification of cell culture-derived proteins.
  • Plan and document experiments, analyze and interpret data, maintain complete technical records, and prepare concise reports and presentations for internal and external stakeholders.
  • Lead or support technology transfer of developed processes to Production and Quality Control, including transfer plans, readiness assessments, training, and on-floor support during initial manufacturing runs.
  • Author and revise development protocols, technical reports, standard operating procedures, batch records, and other controlled documents in accordance with company procedures and applicable ISO 13485 requirements.
  • Evaluate new upstream technologies and potential custom-manufacturing projects, and contribute technical scope, feasibility, resource, timeline, and cost estimates.
  • Maintain a safe, organized, and inspection-ready laboratory, including equipment upkeep, material management, biosafety practices, and compliance with established procedures.
  • Work primarily in a laboratory environment and handle biological materials under established biosafety procedures at Biosafety Level 2 and below.
  • Perform other duties as assigned.
Desired Qualifications
  • Experience in diagnostics, biologics, or another regulated life-science environment.
  • Working knowledge of upstream process scale-up and operation of rocking and/or stirred-tank bioreactors.
  • Experience with relevant characterization methods, such as cell growth and viability measurements, protein-expression assays, and viral infectivity assays, including TCID50 or plaque assays.

About the company

Meridian Bioscience develops, manufactures, markets and distributes diagnostic test kits, rare reagents, specialty biologicals and components for life science and agri-bio research. Its diagnostic products are designed for use outside the body with minimal equipment, delivering accurate and fast results to aid early diagnosis of infections and lead poisoning. The company maintains an end-to-end platform from development to distribution and holds strong positions in gastrointestinal and upper respiratory infections as well as blood lead level testing, while its products also serve as components in other diagnostics. Its goal is to improve patient well-being and reduce health care costs by providing accessible, reliable diagnostics and research materials.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Newtown, Ohio

Founded

1977

Get referred to Meridian Bioscience

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Alethia IVDR clearance opens more European hospital and lab purchasing channels in 2026.
  • June 26, 2024 lyophilized NGS launch and February 18, 2026 expansion deepen life-science sales.
  • New CEO Andy Kitzmiller and CFO Julie Smith, named October 14, 2025, sharpen execution.

What critics are saying

  • SD Biosensor and SJL own Meridian since January 31, 2023, limiting employee equity upside.
  • October 14, 2025 CEO reset signals pressure to accelerate growth after ownership change.
  • 4bases partnership exposes Meridian to partner-dependent commercialization if KaryoSolver adoption stalls.

What makes Meridian Bioscience unique

  • Alethia IVDR certification on February 23, 2026 validates broad European molecular assay reach.
  • Meridian's lyophilized NGS kits eliminate cold-chain shipping, a rare workflow advantage.
  • Health Canada licensed Alethia CMV on July 8, 2026, expanding regulated diagnostics breadth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

9%

2 year growth

9%
Associated Press
Jul 14th, 2026
Meridian Bioscience gains Health Canada licence for rapid CMV diagnostic assay

Meridian Bioscience has received Health Canada licensing for its Alethia CMV assay, expanding its molecular diagnostic offerings in the Canadian market. The assay joins Meridian's existing Alethia menu, which includes tests for C. difficile, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis. The Alethia platform uses LAMP technology to deliver molecular results in under an hour. The CMV assay enables early detection of congenital cytomegalovirus, which affects one in 200 babies annually. Nearly one in four women carry CMV, the most common congenital infection transmitted during pregnancy. The assay uses saliva samples for congenital CMV testing. Meridian Bioscience is a privately held life science company headquartered in Cincinnati, Ohio, serving customers in over 70 countries.

Business Wire
Jun 10th, 2026
Meridian and 4bases partner to scale cytogenetics NGS assay with ambient-stable reagents

Meridian Bioscience has partnered with 4bases to enable global deployment of KaryoSolver, a next-generation cytogenetics assay, through advanced reagent stabilisation technology. The collaboration addresses a critical barrier to scaling NGS workflows: the cold-chain requirements of conventional liquid-based library preparation solutions. Meridian's lyophilisation platform stabilises KaryoSolver's NGS library preparation components, enabling ambient-temperature shipping and storage whilst maintaining diagnostic performance. The technology eliminates refrigerated logistics, extends shelf life, and simplifies global distribution. KaryoSolver consolidates structural variant detection into a single assay with integrated analysis, delivering genomic insights within hours versus days for traditional workflows. The stabilisation breakthrough allows 4bases to expand access to comprehensive genetic diagnosis whilst reducing costs and operational complexity across international markets. Both companies will exhibit at the European Human Genetics Conference in Gothenburg this June.

4bases
Jun 10th, 2026
4bases is happy to announce a collaboration agreement with Meridian Bioscience.

4bases is happy to announce a collaboration agreement with Meridian Bioscience. Ambient-stable NGS workflows, enabled by Meridian's lyophilization expertise, expand global access to 4bases' KaryoSolver(TM), a platform for rapid structural variant analysis. The Life Science division of Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, today announced a collaboration with 4bases SA focused on one critical objective: expanding the accessible market and enhancing the global deployment of KaryoSolver(TM), a next-generation cytogenetics assay, through advanced assay stabilization. KaryoSolver(TM) represents a significant step forward in cytogenetics. Traditional workflows rely on multiple complementary tests, often taking days to deliver a complete picture. In contrast, KaryoSolver(TM) consolidates structural variant detection into a single assay with integrated data analysis, providing actionable genomic insights within hours. However, bringing this innovation to a global market requires overcoming a critical barrier: reagent stability. Conventional liquid-based NGS library preparation solutions are inherently limited by short shelf life, creating significant challenges across the distribution chain, including the cost and complexity of refrigerated shipping and storage that have historically restricted scalable global expansion. Meridian addressed this challenge through its advanced reagent stabilization platform, combining formulation science with optimized enzyme lyophilization technology. By stabilizing the NGS library preparation components, Meridian enabled KaryoSolver(TM) to be shipped and stored at ambient temperatures, eliminating cold-chain requirements, extending shelf life, and simplifying inventory management across the global distribution channels. In addition, lyophilization streamlines manufacturing, supporting more efficient and scalable production. "Our platform technology enabled the transition of the assay into a room-temperature stable format while preserving the performance characteristics required for molecular diagnostics," said Florent Chang-Pi-Hin, Vice President, Research and Development at Meridian Life Science. "By removing cold-chain constraints without sacrificing assay integrity, we're helping expand access to reliable testing worldwide." In this fruitful collaboration, Meridian and 4bases R&D teams joined efforts to optimize Meridian's Lyophilized NGS Enzymatic DNA Fragmentation reagents for the development of a kit to be integratied into 4bases' Oxford Nanopore Technologies workflow, ensuring reliable and efficient sample preparation within the broader assay system. "The idea behind KaryoSolver(TM) is to simplify access to comprehensive genetic diagnosis, and Meridian's expertise in stabilization has been transformative," said Fabio Grandi, COO & Co-Founder at 4bases. "Short shelf life and cold-chain requirements previously limited how far and how efficiently we could scale. With lyophilization, we can now reliably supply our global customers while simplifying logistics, reducing costs, and accelerating the adoption of KaryoSolver(TM) as a rapid, single-workflow solution for cytogenetics." Together, Meridian and 4bases are removing key barriers to advanced genomic testing, pairing breakthrough assay design with the stability, scalability, and operational efficiency required for effective global deployment. 4bases and Meridian Bioscience will both be exhibiting at the upcoming European Human Genetics Conference (ESHG) on June 13-16 in Gothenburg, Sweden, where attendees will have the possibility to learn more about the companies' collaboration and latest advances in ambient-stable next-generation sequencing workflows and cytogenetics solutions. Additional event details, including opportunities to schedule meetings with the Meridian Bioscience and 4bases teams during ESHG, can be found at https://4bases.ch and Meridian Bioscience's events page. Share:

LinkedIn
May 7th, 2025
Excited to announce a strategic investment in heva — an AI-powered… | Raches Ella | 15 comments

Excited to announce a strategic investment in heva — an AI-powered platform transforming cross-border healthcare access! ✈️🌍 India is a premier destination for medical tourism, and heva, founded by Varun & Hector is solving the fragmentation that limits its growth. To healthcare providers: heva helps you focus on delivering world-class care — while they connect you to patients globally. | 15 comments on LinkedIn

PR Newswire
Mar 6th, 2025
Meridian Bioscience Congratulates Catherine Lufkin For Receiving Pure Earth'S 2025 "Force Of Nature" Award

CINCINNATI, March 6, 2025 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, proudly congratulates Catherine Lufkin, Senior Director, Global Point of Care, on being honored with Pure Earth's 2025 "Force of Nature" Award. This prestigious recognition celebrates her leadership and dedication to advancing environmental health, particularly in the fight against lead poisoning.Lufkin is being recognized at Pure Earth's International Women's Day celebration for her unwavering commitment to ensuring access to fast, accurate blood lead testing in communities impacted by lead contamination. Her leadership has been instrumental in Meridian's partnership with Pure Earth, which has provided LeadCare® II blood lead testing technology to under-resourced communities worldwide since 2016. Her dedication to advancing lead testing was also a driving force behind Meridian winning the CDC's Lead Detect Prize, a prestigious competition that fostered the development of innovative, rapid lead detection technologies to enhance public health efforts."We are immensely proud of Catherine's achievements and this well-deserved recognition," said Tony Serafini-Lamanna, President of Meridian Bioscience Diagnostics. "Her work exemplifies our mission to improve global health through innovation and collaboration. In our ongoing partnership with Pure Earth, we remain committed to reducing lead exposure and its harmful effects on vulnerable populations."The LeadCare II system, the only CLIA-waived point-of-care blood lead testing system, is a vital tool in Pure Earth's global efforts to combat lead poisoning